J. Davoren

发表

Design and optimization of selective azaindole amide M1 positive allosteric modulators.

Gregory W. Kauffman, R. Obach, J. Edgerton, 2016, Bioorganic & medicinal chemistry letters.

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor

M. Ehlers, P. Tierney, R. Kozak, 2018, Nature Communications.

Discovery of the Potent and Selective M1 PAM-Agonist N-[(3R,4S)-3-Hydroxytetrahydro-2H-pyran-4-yl]-5-methyl-4-[4-(1,3-thiazol-4-yl)benzyl]pyridine-2-carboxamide (PF-06767832): Evaluation of Efficacy and Cholinergic Side Effects.

Gregory W. Kauffman, J. Edgerton, S. Steyn, 2016, Journal of medicinal chemistry.

Synthesis of 5-bromo-6-methyl imidazopyrazine, 5-bromo and 5-chloro-6-methyl imidazopyridine using electron density surface maps to guide synthetic strategy

David L. Gray, A. Harris, D. Nason, 2011 .

Studies toward the asymmetric total synthesis of solandelactone oxylipins: The total synthesis of solandelactone E

J. Davoren, 2006 .

Discovery and Lead Optimization of Atropisomer D1 Agonists with Reduced Desensitization.

R. Kozak, David L. Gray, B. Rai, 2018, Journal of medicinal chemistry.

Design and Synthesis of γ- and δ-Lactam M1 Positive Allosteric Modulators (PAMs): Convulsion and Cholinergic Toxicity of an M1-Selective PAM with Weak Agonist Activity.

C. Thorn, T. Kenakin, J. Edgerton, 2017, Journal of medicinal chemistry.

Remarkable [3+2] Annulations of Electron-Rich Olefins with Unstabilized Azomethine Ylides

David L. Gray, A. Harris, D. Nason, 2010 .

An approach to the skeleton of the securinega alkaloids. The total synthesis of (+/-)-securinine.

S. Liras, J. Bordner, J. Davoren, 2001, Organic letters.

Studies toward the enantioselective syntheses of oxylipins: total synthesis and structure revision of solandelactone E.

S. Martin, C. Harcken, J. Davoren, 2008, The Journal of organic chemistry.

Measurement of atropisomer racemization kinetics using segmented flow technology.

Scot Mente, Jennifer E Davoren, Mark W Bundesmann, 2012, ACS medicinal chemistry letters.

Targeting mitochondria.

P. Wipf, M. Fink, V. Kagan, 2008, Accounts of chemical research.

Enantioselective synthesis and structure revision of solandelactone E.

S. Martin, J. Davoren, 2007, Journal of the American Chemical Society.

Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284

J. Edgerton, S. Grimwood, D. Smith, 2016, Molecular Pharmacology.

Inositol Phosphate Accumulation in Vivo Provides a Measure of Muscarinic M1 Receptor Activation.

J. Edgerton, V. Reinhart, S. Grimwood, 2016, Biochemistry.

Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation

Graham V. Williams, T. Kiss, M. Hajós, 2020, Frontiers in Pharmacology.

An experimental survey of the transition between two-state and downhill protein folding scenarios

Amelia A. Fuller, Martin Gruebele, Peter Wipf, 2008, Proceedings of the National Academy of Sciences.

Discovery of a novel Kv7 channel opener as a treatment for epilepsy.

Lei Zhang, R. J. Mather, Christopher R Butler, 2015, Bioorganic & medicinal chemistry letters.

Impaired β-arrestin recruitment and reduced desensitization by non-catechol agonists of the D1 dopamine receptor

M. Ehlers, P. Tierney, R. Kozak, 2018, Nature Communications.

Targeting mitochondria.

P. Wipf, M. Fink, V. Kagan, 2008, Accounts of chemical research.

Characterization of a Novel M1 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator Radioligand, [3H]PT-1284

J. Edgerton, S. Grimwood, D. Smith, 2016, Molecular Pharmacology.